Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

442 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
The efficacy of triplet antiemetic therapy with 0.75 mg of palonosetron for chemotherapy-induced nausea and vomiting in lung cancer patients receiving highly emetogenic chemotherapy.
Miura S, Watanabe S, Sato K, Makino M, Kobayashi O, Miyao H, Iwashima A, Okajima M, Tanaka J, Tanaka H, Kagamu H, Yokoyama A, Narita I, Yoshizawa H. Miura S, et al. Among authors: okajima m. Support Care Cancer. 2013 Sep;21(9):2575-81. doi: 10.1007/s00520-013-1835-2. Epub 2013 May 5. Support Care Cancer. 2013. PMID: 23644992 Clinical Trial.
Prognostic significance of the radiologic features of pneumonitis induced by anti-PD-1 therapy.
Watanabe S, Ota T, Hayashi M, Ishikawa H, Otsubo A, Shoji S, Nozaki K, Ichikawa K, Kondo R, Miyabayashi T, Miura S, Tanaka H, Abe T, Okajima M, Terada M, Ishida T, Iwashima A, Sato K, Yoshizawa H, Kikuchi T. Watanabe S, et al. Among authors: okajima m. Cancer Med. 2020 May;9(9):3070-3077. doi: 10.1002/cam4.2974. Epub 2020 Mar 9. Cancer Med. 2020. PMID: 32150668 Free PMC article.
Critical Roles of Chemoresistant Effector and Regulatory T Cells in Antitumor Immunity after Lymphodepleting Chemotherapy.
Saida Y, Watanabe S, Tanaka T, Baba J, Sato K, Shoji S, Igarashi N, Kondo R, Okajima M, Koshio J, Ichikawa K, Nozaki K, Ishikawa D, Koya T, Miura S, Tanaka J, Kagamu H, Yoshizawa H, Nakata K, Narita I. Saida Y, et al. Among authors: okajima m. J Immunol. 2015 Jul 15;195(2):726-35. doi: 10.4049/jimmunol.1401468. Epub 2015 Jun 3. J Immunol. 2015. PMID: 26041539
Observational study of rebiopsy in EGFR-TKI-resistant patients with EGFR mutation-positive advanced NSCLC.
Koyama K, Miura S, Watanabe S, Shoji S, Koshio J, Hayashi Y, Ishikawa D, Sato K, Miyabayashi T, Okajima M, Ota T, Tanaka T, Matsumoto N, Kuriyama H, Abe T, Nozaki K, Ichikawa K, Kondo R, Tanaka H, Kikuchi T. Koyama K, et al. Among authors: okajima m. Sci Rep. 2022 Apr 16;12(1):6367. doi: 10.1038/s41598-022-10288-8. Sci Rep. 2022. PMID: 35430596 Free PMC article.
Phase II study of nanoparticle albumin-bound paclitaxel monotherapy for relapsed non-small cell lung cancer with patient-reported outcomes (NLCTG1302).
Shoji S, Miura S, Watanabe S, Ohtsubo A, Nozaki K, Saida Y, Ichikawa K, Kondo R, Tanaka T, Koyama K, Tanaka H, Okajima M, Abe T, Ota T, Ishida T, Makino M, Iwashima A, Sato K, Matsumoto N, Yoshizawa H, Kikuchi T. Shoji S, et al. Among authors: okajima m. Transl Lung Cancer Res. 2022 Jul;11(7):1359-1368. doi: 10.21037/tlcr-22-89. Transl Lung Cancer Res. 2022. PMID: 35958345 Free PMC article.
442 results